8-K: Apogee Therapeutics Announces Positive Phase 1 Results for APG777 and Reports 2023 Financials

Apogee Therapeutics reports positive interim Phase 1 results for APG777, showing a 75-day half-life and plans for a Phase 2 trial, along with full year 2023 financial results.

Summary

• Apogee Therapeutics announced positive interim results from its Phase 1 trial of APG777, a novel antibody for atopic dermatitis, showing a half-life of approximately 75 days.
• The trial results exceeded objectives, supporting potential for less frequent dosing and improved clinical responses compared to current treatments.
• APG777 demonstrated deep and sustained inhibition of key biomarkers for about 3 months.
• The company plans to initiate a Phase 2 clinical trial for APG777 in the first half of 2024.
• Apogee also reported its full year 2023 financial results, with a cash position of $395.5 million at year-end.
• The company expects its cash runway to extend into the fourth quarter of 2026.
• Research and development expenses were $68.4 million for the year ended December 31, 2023.
• The net loss for the year was $84.0 million, primarily due to increased R&D and G&A expenses.
• Apogee's second program, APG808, is set to start a Phase 1 trial ahead of schedule following regulatory clearance in February.
• The company is also progressing its earlier-stage programs, APG990 and APG222.

Sentiment

Score: 8

Explanation: The document conveys a highly positive sentiment due to the strong Phase 1 results for APG777, the company's solid financial position, and the advancement of multiple pipeline programs. The company is exceeding expectations and has a clear path forward.

Positives

• APG777 demonstrated a potentially best-in-class pharmacokinetic profile with a 75-day half-life.
• The Phase 1 trial results for APG777 exceeded expectations, showing strong biomarker inhibition.
• The company has a strong cash position of $395.5 million, providing a runway into 4Q 2026.
• The Phase 2 trial for APG777 is planned to start in the first half of 2024, ahead of schedule.
• APG808's Phase 1 trial is also starting ahead of schedule.
• APG777 is well tolerated with a favorable safety profile.
• The company is advancing multiple pipeline programs, including APG990 and APG222.

Negatives

• The company reported a net loss of $84.0 million for the year ended December 31, 2023.
• Research and development expenses increased significantly to $68.4 million for the year ended December 31, 2023.
• General and administrative expenses also increased to $24.6 million for the year ended December 31, 2023.

Risks

• The company's future success depends on the outcome of clinical trials, which are subject to various risks and uncertainties.
• There is no guarantee that APG777 or other pipeline candidates will receive regulatory approval.
• The company's financial performance is subject to market conditions and other factors beyond its control.
• The company is subject to risks related to global macroeconomic conditions and volatility.
• There is a risk that clinical trial results may not correlate with preclinical study results.

Future Outlook

Apogee expects its existing cash to fund operations into 4Q 2026 and plans to advance its pipeline programs, including initiating Phase 2 trials for APG777 and Phase 1 trials for APG808, while also progressing earlier-stage programs.

Management Comments

• Michael Henderson, M.D., Chief Executive Officer of Apogee, stated that 2023 was a momentous year for the company with the completion of a successful IPO and initiation of the first clinical program of APG777.
• Michael Henderson, M.D., also mentioned that the positive interim results from the Phase 1 trial of APG777 demonstrated a favorable safety profile and exceeded trial objectives.
• Carl Dambkowski, M.D., Chief Medical Officer of Apogee Therapeutics, expressed gratitude to the volunteers, investigator, and the study team for their support in the successful execution of the Phase 1 trial.

Industry Context

The announcement is significant in the context of the atopic dermatitis treatment landscape, where current therapies often require frequent injections. Apogee's APG777, with its extended half-life, aims to address this limitation by offering less frequent dosing, potentially improving patient adherence and outcomes. The company is also targeting other inflammatory and immunology indications, which are areas of high unmet need.

Comparison to Industry Standards

• APG777's 75-day half-life is significantly longer than existing treatments for atopic dermatitis, such as Dupixent and lebrikizumab, which require injections every two to four weeks.
• The planned Phase 2 trial for APG777 aims to achieve 30-40% greater exposures than lebrikizumab during induction, potentially leading to improved clinical responses.
• The company is also developing APG808, which targets IL-4R, similar to Dupixent, but with an extended half-life.
• Apogee's approach of targeting OX40L with APG990 and APG222 represents a novel approach compared to current treatments that primarily target IL-13 and IL-4R.

Related Party Transactions

• Dr. Silverberg and Dr. Guttman-Yassky receive financial compensation as scientific advisors for Apogee.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and financial position.
• Patients with atopic dermatitis and other inflammatory diseases may benefit from the development of new and improved treatments.
• Employees are likely to be motivated by the company's progress and positive outlook.
• The company's success could lead to increased opportunities for suppliers and partners.

Next Steps

• Initiate a randomized, placebo-controlled Phase 2 clinical trial for APG777 in patients with moderate-to-severe atopic dermatitis in the first half of 2024.
• Start a Phase 1 healthy volunteer clinical trial for APG808 ahead of schedule.
• Advance earlier-stage programs, APG990 and APG222, towards candidate selection.
• Provide more detailed updates on earlier pipeline programs and combination strategy in an R&D Day in Q4 2024.
• Evaluate APG777 in expansion indications, including initiating a Phase 2 trial in asthma in 2025.

Key Dates

Keywords

APG777, atopic dermatitis, clinical trial, half-life, IL-13, biologics, APG808, Phase 1, Phase 2, pharmacokinetics, pharmacodynamics, R&D, cash runway, monoclonal antibody, inflammation